Pear Therapeutics' Digital Therapeutic For Insomnia Shows Meaningful Reductions In Severity Through 6 Months

Pear Therapeutics Inc PEAR announced data that further underscore the effectiveness of Somryst for chronic insomnia at the World Sleep 2022.
Interim data from the DREAM study, analyzed in mid-Q1 2022, had 991 patients enrolled to date.
In 779 patients who completed end-of-treatment (EOT), the population achieved statistically significant and clinically meaningful reductions in insomnia severity (ISI), sleep onset latency (SOL), and wake-after-sleep onset (WASO) from baseline to post-treatment at nine weeks.
In the 193 patients who completed the six-month follow-up, significant improvements in ISI, SOL, and WASO were maintained through six months.
Interim data showed that of participants treated with Somryst, the mean ISI at baseline was 18.8, and at EOT was found to be 11.3, and at six months 12.1.
By the end of treatment, 78.7% and 73.3% of participants treated with Somryst achieved the clinically meaningful definition of SOL remission (falling sleeping within 30 minutes or less) and/or WASO remission, respectively.
Similar patterns in WASO, SOL, sleep efficiency and sleep quality were also demonstrated in an additional study evaluating older adults (55 years of age or older).
Somryst is an FDA-authorized 9-week prescription digital therapeutic (PDT) that addresses the underlying issues of chronic insomnia by delivering cognitive behavioral therapy for insomnia.
Price Action: PEAR shares are up 10.30% at $4.61 during the market session on the last check Tuesday.